دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
In the Literature
doi : 10.1093/cid/ciac094
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages i–ii
Higher Comorbidity Burden Predicts Worsening Neurocognitive Trajectories in People with Human Immunodeficiency Virus
Ronald J Ellis, Emily Paolillo, Rowan Saloner, Robert K Heaton
doi : 10.1093/cid/ciab655
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1323–1328,
Age-related comorbidities accumulate faster in people with HIV (PWH) than in those without HIV. We evaluated whether a validated multimorbidity scale, the Charlson index, predicted neurocognitive trajectories in PWH.
Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)
Shekhar Ghamande, Courtney Shaver, Kempapura Murthy, Chandni Raiyani, Heath D White, Tasnim Lat, Alejandro C Arroliga, Dayna Wyatt, H Keipp Talbot, Emily T Martin, Arnold S Monto, Richard K Zimmerman, Donald B Middleton, Fernanda P Silveira, Jill M Ferdinands, Manish M Patel, Manjusha Gaglani
doi : 10.1093/cid/ciab654
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1329–1337
Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015–2016 to 2017–2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Chronic Disease and Immunosuppression Increase the Risk for Nonvaccine Serotype Pneumococcal Disease: A Nationwide Population-based Study
Pontus Naucler, Ilias Galanis, Alexandros Petropoulos, Fredrik Granath, Eva Morfeldt, Åke Örtqvist, Birgitta Henriques-Normark
doi : 10.1093/cid/ciab651
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1338–1349
Demography is changing, with people living longer with comorbidities. In this nationwide population-based study, we investigated the serotype-specific invasive pneumococcal disease (IPD) risk in individuals with comorbidities, and effects of the pneumococcal conjugated vaccine (PCV) child immunization program.
CD4+ T-Cell Count at Antiretroviral Therapy Initiation in the “Treat-All� Era in Rural South Africa: An Interrupted Time Series Analysis
H Manisha Yapa, Hae-Young Kim, Kathy Petoumenos, Frank A Post, Awachana Jiamsakul, Jan-Walter De Neve, Frank Tanser, Collins Iwuji, Kathy Baisley, Maryam Shahmanesh, Deenan Pillay, Mark J Siedner, Till Bärnighausen, Jacob Bor
doi : 10.1093/cid/ciab650
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1350–1359
South Africa implemented universal test and treat (UTT) in September 2016 in an effort to encourage earlier initiation of antiretroviral therapy (ART).
CD4 Cell Count: A Critical Tool in the Human Immunodeficiency Virus Response
Nathan Ford, Tom Chiller
doi : 10.1093/cid/ciab658
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1360–1361
Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials
Kaatje Bollaerts, Mark A Fletcher, Jose A Suaya, Germaine Hanquet, Marc Baay, Bradford D Gessner
doi : 10.1093/cid/ciab649
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1362–1371
Vaccine regulatory decision making is based on vaccine efficacy against etiologically confirmed outcomes, which may underestimate the preventable disease burden. To quantify this underestimation, we compared vaccine-preventable disease incidence (VPDI) of clinically defined outcomes with radiologically/etiologically confirmed outcomes.
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children
Kendra K Radtke, Anneke C Hesseling, J L Winckler, Heather R Draper, Belen P Solans, Stephanie Thee, Lubbe Wiesner, Louvina E van der Laan, Barend Fourie, James Nielsen, H Simon Schaaf, Radojka M Savic, Anthony J Garcia-Prats
doi : 10.1093/cid/ciab641
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1372–1381
Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB.
Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California
Kristin L Andrejko, Jake Pry, Jennifer F Myers, Nicholas P Jewell, John Openshaw, James Watt, Seema Jain, Joseph A Lewnard, California COVID-19 Case-Control Study Team
doi : 10.1093/cid/ciab640
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1382–1389
Estimates of coronavirus disease 2019 (COVID-19) vaccine effectiveness under real-world conditions, and understanding of barriers to uptake, are necessary to inform vaccine rollout.
Chest X-ray Analysis With Deep Learning-Based Software as a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-Analysis of Diagnostic Accuracy
Gamuchirai Tavaziva, Miriam Harris, Syed K Abidi, Coralie Geric, Marianne Breuninger, Keertan Dheda, Aliasgar Esmail, Monde Muyoyeta, Klaus Reither, Arman Majidulla, Aamir J Khan, Jonathon R Campbell, Pierre-Marie David, Claudia Denkinger, Cecily Miller, Ruvandhi Nathavitharana, Madhukar Pai, Andrea Benedetti, Faiz Ahmad Khan
doi : 10.1093/cid/ciab639
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1390–1400
Automated radiologic analysis using computer-aided detection software (CAD) could facilitate chest X-ray (CXR) use in tuberculosis diagnosis. There is little to no evidence on the accuracy of commercially available deep learning-based CAD in different populations, including patients with smear-negative tuberculosis and people living with human immunodeficiency virus (HIV, PLWH).
Remediation of Mucorales-contaminated Healthcare Linens at a Laundry Facility Following an Investigation of a Case Cluster of Hospital-acquired Mucormycosis
Alexander J Sundermann, Cornelius J Clancy, A William Pasculle, Guojun Liu, Shaoji Cheng, Richard B Cumbie, Eileen Driscoll, Ashley Ayres, Lisa Donahue, Michael Buck, Andrew Streifel, Carlene A Muto, M Hong Nguyen
doi : 10.1093/cid/ciab638
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1401–1407
In an investigation of hospital-acquired mucormycosis cases among transplant recipients, healthcare linens (HCLs) delivered to our center were found to be contaminated with Mucorales. We describe an investigation and remediation of Mucorales contamination at the laundry supplying our center.
Association of Adverse Events With Antibiotic Treatment for Urinary Tract Infection
Anne M Butler, Michael J Durkin, Matthew R Keller, Yinjiao Ma, William G Powderly, Margaret A Olsen
doi : 10.1093/cid/ciab637
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1408–1418
Little is known about the relative harms of different antibiotic regimens prescribed to treat uncomplicated urinary tract infection (UTI). We sought to compare the risk of adverse events associated with commonly used oral antibiotic regimens for the outpatient treatment of uncomplicated UTI.
An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern
C Paul Morris, Chun Huai Luo, Adannaya Amadi, Matthew Schwartz, Nicholas Gallagher, Stuart C Ray, Andrew Pekosz, Heba H Mostafa
doi : 10.1093/cid/ciab636
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1419–1428
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants concerning for enhanced transmission, evasion of immune responses, or associated with severe disease have motivated the global increase in genomic surveillance. In the current study, large-scale whole-genome sequencing was performed between November 2020 and the end of March 2021 to provide a phylodynamic analysis of circulating variants over time. In addition, we compared the viral genomic features of March 2020 and March 2021.
Deliberation, Dissent, and Distrust: Understanding Distinct Drivers of Coronavirus Disease 2019 Vaccine Hesitancy in the United States
Khai Hoan Tram, Sahar Saeed, Cory Bradley, Branson Fox, Ingrid Eshun-Wilson, Aaloke Mody, Elvin Geng
doi : 10.1093/cid/ciab633
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1429–1441
Despite the availability of safe and efficacious coronavirus disease 2019 vaccines, a significant proportion of the American public remains unvaccinated and does not appear to be immediately interested in receiving the vaccine.
Prediction Rules for Ruling Out Endocarditis in Patients With Staphylococcus aureus Bacteremia
Thomas W van der Vaart, Jan M Prins, Robin Soetekouw, Gitte van Twillert, Jan Veenstra, Bjorn L Herpers, Wouter Rozemeijer, Rogier R Jansen, Marc J M Bonten, Jan T M van der Meer
doi : 10.1093/cid/ciab632
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1442–1449
Staphylococcus aureus bacteremia (SAB) is in 10% to 20% of cases complicated by infective endocarditis. Clinical prediction scores may select patients with SAB at highest risk for endocarditis, improving the diagnostic process of endocarditis.
Clinical Improvement, Outcomes, Antiviral Activity, and Costs Associated With Early Treatment With Remdesivir for Patients With Coronavirus Disease 2019 (COVID-19)
Carlos K H Wong, Kristy T K Lau, Ivan C H Au, Xi Xiong, Eric H Y Lau, Benjamin J Cowling
doi : 10.1093/cid/ciab631
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1450–1458
Evidence remains inconclusive on any significant benefits of remdesivir in patients with mild-to-moderate COVID-19. This study explored the disease progression, various clinical outcomes, changes in viral load, and costs associated with early remdesivir treatment among COVID-19 patients.
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Céline Boutry, Andrew Hastie, Javier Diez-Domingo, Juan Carlos Tinoco, Chong-Jen Yu, Charles Andrews, Jean Beytout, Covadonga Caso, Huey-Shinn Cheng, Hee Jin Cheong, Eun Ju Choo, Dan Curiac, Emmanuel Di Paolo, Marc Dionne, Tamara Eckermann, Meral Esen, Murdo Ferguson, Wayne Ghesquiere, Shinn-Jang Hwang, Thiago Junqueira Avelino-Silva, Pavel Kosina, Chiu-Shong Liu, Jukka Markkula, Beate Moeckesch, Cláudia Murta de Oliveira, Dae Won Park, Karlis Pauksens, Paola Pirrotta, Georg Plassmann, Carol Pretswell, Lars Rombo, Bruno Salaun, Johan Sanmartin Berglund, Isabelle Schenkenberger, Tino Schwarz, Meng Shi, Benita Ukkonen, Toufik Zahaf, Cristiano Zerbini, Anne Schuind, Anthony L Cunningham, Zoster-049 Study Group
doi : 10.1093/cid/ciab629
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1459–1467
This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age ≥50 years in 2 pivotal efficacy trials (ZOE-50 and ZOE-70).
Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group
Huyen Nguyen, Benjamin Hampel, David Garcia Nuñez, Manuel Battegay, Anna Hachfeld, Enos Bernasconi, Alexandra Calmy, Matthias Cavassini, Pietro Vernazza, Jacques Fellay, Hannes Rudolph, Michael Huber, Karoline Leuzinger, Matthieu Perreau, Alexandra Scherrer, Alban Nicolas Ramette, Sabine Yerly, Huldrych F Günthard, Roger D Kouyos, Katharina Kusejko, Swiss HIV Cohort Study
doi : 10.1093/cid/ciab628
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1468–1475
As trans women are disproportionately affected by the HIV epidemic, and are still understudied, we aimed to identify and characterize the trans women in the Swiss HIV Cohort Study (SHCS).
Pre-Hospital Administration of Remdesivir During a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak in a Skilled Nursing Facility
Megan A Dunay, Sarah L McClain, Rick L Holloway, Sarah L W Norris, Talie Bendixsen Randall, Caitlin E Mohr, Brent H Sasaki, Joseph A Coones, Nicholas J Vietri
doi : 10.1093/cid/ciab715
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1476–1479
Completion of a 5-day course of remdesivir was associated with approximately 17-fold increased odds of survival among a sample of 54 nursing home residents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the course of an outbreak from October to December 2020. Remdesivir was well tolerated; administration was logistically feasible in a pre-hospital environment.
Pharyngeal Chlamydia trachomatis in Men Who Have Sex With Men (MSM) in The Netherlands: A Large Retrospective Cohort Study
Ymke J Evers, Nicole H T M Dukers-Muijrers, Geneviève A F S van Liere, Jan van Bergen, Sophie Kuizenga-Wessel, Christian J P A Hoebe
doi : 10.1093/cid/ciab685
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1480–1484
Pharyngeal Chlamydia trachomatis (CT) was diagnosed in 1.2% and pharyngeal-only CT in 0.5% of routinely universally tested men who have sex with men (MSM). In these 3-anatomic-site tested MSM, pharyngeal-only CT comprised 4.8% of all CT. The low positivity of pharyngeal-only CT indicates low public health impact of pharyngeal CT.
False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine
Kelvin Kai-Wang To, Xin Li, David Christopher Lung, Jonathan Daniel Ip, Wan-Mui Chan, Allen Wing-Ho Chu, Cyril Chik-Yan Yip, Jonathan H K Chen, Rosana Wing-Shan Poon, Hoi-Wah Tsoi, Raymond Wai-Man Lai, Wing-Kin To, Lili Ren, Mingkun Li, Yunlong Cao, Xiaoliang Sunney Xie, Dong-Yan Jin, Kwok-Yung Yuen
doi : 10.1093/cid/ciab684
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1485–1488
A false-positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction result can lead to unnecessary public health measures. We report 2 individuals whose respiratory specimens were contaminated by an inactivated SARS-CoV-2 vaccine strain (CoronaVac), likely at vaccination premises. Incidentally, whole genome sequencing of CoronaVac showed adaptive deletions on the spike protein, which do not result in observable changes of antigenicity.
Suspected Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Reinfections: Incidence, Predictors, and Healthcare Use Among Patients at 238 US Healthcare Facilities, 1 June 2020 to 28 February 2021
Alexander Lawandi, Sarah Warner, Junfeng Sun, Cumhur Y Demirkale, Robert L Danner, Michael Klompas, Adi Gundlapalli, Deblina Datta, Aaron M Harris, Sapna Bamrah Morris, Pavithra Natarajan, Sameer S Kadri
doi : 10.1093/cid/ciab671
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1489–1492
In a retrospective cohort study, among 131 773 patients with previous coronavirus disease 2019 (COVID-19), reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was suspected in 253 patients (0.2%) at 238 US healthcare facilities between 1 June 2020 and 28 February 2021. Women displayed a higher cumulative reinfection risk. Healthcare burden and illness severity were similar between index and reinfection encounters.
A 47-Year-Old Woman With a Breast Infection After Mastopexy
Surksha Sirichand, Miguel E Cervera-Hernandez, Susan Fineberg, Chitra Punjabi
doi : 10.1093/cid/ciab624
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1493–1495
Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: An Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document
Alexander L Greninger, Jennifer Dien Bard, Robert C Colgrove, Erin H Graf, Kimberly E Hanson, Mary K Hayden, Romney M Humphries, Christopher F Lowe, Melissa B Miller, Dylan R Pillai, Daniel D Rhoads, Joseph D Yao, Francesca M Lee
doi : 10.1093/cid/ciab761
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1496–1502
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with >2 million genomes sequenced at this writing. The rise of more transmissible variants of concern that affect vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution.
Does Previous Syphilis Alter the Course of Subsequent Episodes of Syphilis?
Maarten F Schim van der Loeff, Hélène Zondag, Sylvia Bruisten, Vita W Jongen
doi : 10.1093/cid/ciab819
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Page 1503
Response to Schim van der Loeff, et al
Christina M Marra, Clare L Maxwell
doi : 10.1093/cid/ciab820
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1503–1504
Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab
Man Man Niu, Yue Cao, Rui Xue Li, Guo Zhen Fan, Peng Hu
doi : 10.1093/cid/ciab816
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Page 1504
Reinfections Are More Frequent Than Currently Considered in Countries With High Incidence of Coronavirus Disease 2019 (COVID-19) Cases Due to Stringent Definitions
Luis Pampa-Espinoza, Javier Silva-Valencia, Manuel Fernandez-Navarro, Carlos Padilla-Rojas, Lely Solari
doi : 10.1093/cid/ciab783
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1505–1506
Tuberculosis Preventive Therapy for People With Diabetes Mellitus
Willyhelmina Olomi, Irene Andia Biraro, Kajiru Kilonzo, Lindsey te Brake, Davis Kibirige, Nyasatu Chamba, Nyanda Elias Ntinginya, Issa Sabi, Julia Critchley, Katrina Sharples, Philip C Hill, Reinout Van Crevel
doi : 10.1093/cid/ciab755
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1506–1507
Reply to van Crevel, et al
Hung-Ling Huang, Wei-Chang Huang, Meng-Rui Lee, Inn-Wen Chong, Jann-Yuan Wang
doi : 10.1093/cid/ciab756
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1507–1508
Correction to: Salmonella Typhi From Blood Cultures in the Democratic Republic of the Congo: A 10-Year Surveillance
Bieke Tack, Marie-France Phoba, Sandra Van Puyvelde, Lisette M Kalonji, Liselotte Hardy, Barbara Barbé, Marianne A B Van der Sande, Elise Monsieurs, Stijn Deborggraeve, Octavie Lunguya, Jan Jacobs
doi : 10.1093/cid/ciac145
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Pages 1509–1512
Corrigendum to: Factors Associated With Parental Acceptance of Minimally Invasive Tissue Sampling to Identify the Causes of Stillbirth and Neonatal Death
Shiyam Sunder Tikmani, Sarah Saleem, Janet L Moore, Sayyeda Reza, Guruprasad Gowder, Sangappa Dhaded, S Yogeshkumar, Shivaprasad S Goudar, Vardendra Kulkarni, Sunil Kumar, Anna Aceituno, Lindsay Parlberg, Elizabeth M McClure, Robert L Goldenberg
doi : 10.1093/cid/ciac083
Clinical Infectious Diseases, Volume 74, Issue 8, 15 April 2022, Page 1513
Centers for Disease Control and Prevention’s Sexually Transmitted Diseases Infection Guidelines
Kimberly A Workowski, Laura H Bachmann
doi : 10.1093/cid/ciab1055
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S89–S94
Management of Neisseria gonorrhoeae in the United States: Summary of Evidence From the Development of the 2020 Gonorrhea Treatment Recommendations and the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines
Lindley A Barbee, Sancta B St. Cyr
doi : 10.1093/cid/ciac043
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S95–S111
Neisseria gonorrhoeae has developed resistance to all first-line recommended therapies, making gonococcal antimicrobial resistance a major public health concern given limited antibiotic options currently and an even smaller antimicrobial development pipeline.
Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines
William M Geisler, Jane S Hocking, Toni Darville, Byron E Batteiger, Robert C Brunham
doi : 10.1093/cid/ciac126
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S112–S126
To prepare for the development of the 2021 Centers for Disease Control and Prevention (CDC) sexually transmitted infections treatment guidelines, the CDC convened a committee of expert consultants in June 2019 to discuss recent abstracts and published literature on the epidemiology, diagnosis, and management of sexually transmitted infections.This paper summarizes the key questions, evidence, and recommendations for the diagnosis and management of uncomplicated Chlamydia trachomatis (CT) infections in adolescents and adults that were reviewed and discussed for consideration in developing the guidelines.
Management of Adult Syphilis: Key Questions to Inform the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines
Susan Tuddenham, Khalil G Ghanem
doi : 10.1093/cid/ciac060
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S127–S133
A panel of experts generated 5 “key questions� in the management of adult syphilis. A systematic literature review was conducted and tables of evidence were constructed to answer these questions. Available data suggest no clinical benefit to >1 dose of benzathine penicillin G for early syphilis in human immunodeficiency virus (HIV)–infected patients.
Diagnosis and Management of Genital Herpes: Key Questions and Review of the Evidence for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines
Christine Johnston
doi : 10.1093/cid/ciab1056
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S134–S143
Genital herpes, caused by herpes simplex virus (HSV) type 1 or type 2, is a prevalent sexually transmitted infection (STI). Given that HSV is an incurable infection, there are important concerns about appropriate use of diagnostic tools, management of infection, prevention of transmission to sexual partners, and appropriate counseling. In preparation for updating the Centers for Disease Control and Prevention (CDC) STI treatment guidelines, key questions for management of genital herpes infection were developed with a panel of experts. To
Diagnosis and Management of Bacterial Vaginosis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines
Christina A Muzny, Jennifer Balkus, Caroline Mitchell, Jack D Sobel, Kimberly Workowski, Jeanne Marrazzo, Jane R Schwebke
doi : 10.1093/cid/ciac021
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S144–S151
In preparation for the 2021 Centers for Disease Control and Prevention (CDC) sexually transmitted infections (STIs) treatment guidelines, the CDC convened an advisory group in 2019 to examine recent literature addressing updates in the epidemiology, diagnosis, and management of STIs.
Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines
Patricia J Kissinger, Charlotte A Gaydos, Arlene C Seña, R Scott McClelland, David Soper, W Evan Secor, Davey Legendre, Kimberly A Workowski, Christina A Muzny
doi : 10.1093/cid/ciac030
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S152–S161
Trichomonas vaginalis is likely the most prevalent nonviral sexually transmitted infection, affecting an estimated 3.7 million women and men in the United States.
Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines
Paul Nyirjesy, Carolyn Brookhart, Gweneth Lazenby, Jane Schwebke, Jack D Sobel
doi : 10.1093/cid/ciab1057
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S162–S168
Vulvovaginal candidiasis (VVC) is a common cause of vulvovaginal itching and discharge. This article discusses the latest CDC STI Treatment Guidelines for VVC.
Enteric Infections in Men Who Have Sex With Men
Candice J McNeil, Robert D Kirkcaldy, Kimberly Workowski
doi : 10.1093/cid/ciac061
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S169–S178
Enteric pathogens are often associated with exposure to food, water, animals, and feces from infected individuals. However, in sexual networks of men who have sex with men (MSM), transmission of enteric pathogens may occur during direct or indirect oral–anal contact.
Anal Cancer Screening and Prevention: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Guidelines
Luis F Barroso, II, Elizabeth A Stier, Richard Hillman, Joel Palefsky
doi : 10.1093/cid/ciac044
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S179–S192
In June 2019 the Centers for Disease Control and Prevention (CDC) convened an advisory group to assist in development of the 2021 CDC sexually transmitted infections (STI) guidelines.
Prevalence and Management of Sexually Transmitted Infections in Correctional Settings: A Systematic Review
Anne C Spaulding, Zainab Rabeeah, Myrna del Mar González-Montalvo, Matthew J Akiyama, Brenda J Baker, Heidi M Bauer, Brent R Gibson, Ank E Nijhawan, Farah Parvez, Zoon Wangu, Philip A Chan, Rollins Investigational Team on STIs in Corrections
doi : 10.1093/cid/ciac122
Clinical Infectious Diseases, Volume 74, Issue Supplement_2, 15 April 2022, Pages S193–S217
Admissions to jails and prisons in the United States number 10 million yearly; persons entering locked correctional facilities have high prevalence of sexually transmitted infections (STIs).
